• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc. (Amendment)

    2/9/24 5:08:58 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SYRS alert in real time by email
    SC 13G/A 1 d771032dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. 2)

     

     

    Syros Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    87184Q107

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 87184Q107       13G

     

    1 

      

    NAMES OF REPORTING PERSONS

     

    Invus Public Equities, L.P.

    2 

      

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐  (b) ☐

     

    3 

      

    SEC USE ONLY

     

    4 

      

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    3,568,842*

       6    

    SHARED VOTING POWER

     

    0

       7    

    SOLE DISPOSITIVE POWER

     

    3,568,842*

       8    

    SHARED DISPOSITIVE POWER

     

    0

    9 

      

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,842*

    10 

      

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11 

      

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12 

      

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

    *

    See Item 4.

     

    2


    CUSIP No. 87184Q107       13G

     

    1 

      

    NAMES OF REPORTING PERSONS

     

    Invus Public Equities Advisors, LLC

    2 

      

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3 

      

    SEC USE ONLY

     

    4 

      

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    3,568,842*

       6    

    SHARED VOTING POWER

     

    0

       7    

    SOLE DISPOSITIVE POWER

     

    3,568,842*

       8    

    SHARED DISPOSITIVE POWER

     

    0

    9 

      

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,842*

    10 

      

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11 

      

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12 

      

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    See Item 4.

     

    3


    CUSIP No. 87184Q107       13G

     

    1 

      

    NAMES OF REPORTING PERSONS

     

    Artal International S.C.A.

    2 

      

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3 

      

    SEC USE ONLY

     

    4 

      

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    3,568,842*

       6    

    SHARED VOTING POWER

     

    0

       7    

    SOLE DISPOSITIVE POWER

     

    3,568,842*

       8    

    SHARED DISPOSITIVE POWER

     

    0

    9 

      

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,842*

    10 

      

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11 

      

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12 

      

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    See Item 4.

     

    4


    CUSIP No. 87184Q107       13G

     

    1 

      

    NAMES OF REPORTING PERSONS

     

    Artal International Management S.A.

    2 

      

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3 

      

    SEC USE ONLY

     

    4 

      

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    3,568,842*

       6    

    SHARED VOTING POWER

     

    0

       7    

    SOLE DISPOSITIVE POWER

     

    3,568,842*

       8    

    SHARED DISPOSITIVE POWER

     

    0

    9 

      

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,842*

    10 

      

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11 

      

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12 

      

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    See Item 4.

     

    5


    CUSIP No. 87184Q107       13G

     

    1 

      

    NAMES OF REPORTING PERSONS

     

    Artal Group S.A.

    2 

      

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3 

      

    SEC USE ONLY

     

    4 

      

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    3,568,842*

       6    

    SHARED VOTING POWER

     

    0

       7    

    SOLE DISPOSITIVE POWER

     

    3,568,842*

       8    

    SHARED DISPOSITIVE POWER

     

    0

    9 

      

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,842*

    10 

      

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11 

      

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12 

      

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    See Item 4.

     

    6


    CUSIP No. 87184Q107       13G

     

    1 

      

    NAMES OF REPORTING PERSONS

     

    Westend S.A.

    2 

      

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3 

      

    SEC USE ONLY

     

    4 

      

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    3,568,842*

       6    

    SHARED VOTING POWER

     

    0

       7    

    SOLE DISPOSITIVE POWER

     

    3,568,842*

       8    

    SHARED DISPOSITIVE POWER

     

    0

    9 

      

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,842*

    10 

      

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11 

      

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12 

      

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    See Item 4.

     

    7


    CUSIP No. 87184Q107       13G

     

    1 

      

    NAMES OF REPORTING PERSONS

     

    Stichting Administratiekantoor Westend

    2 

      

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3 

      

    SEC USE ONLY

     

    4 

      

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    The Netherlands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    3,568,842*

       6    

    SHARED VOTING POWER

     

    0

       7    

    SOLE DISPOSITIVE POWER

     

    3,568,842*

       8    

    SHARED DISPOSITIVE POWER

     

    0

    9 

      

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,842*

    10 

      

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11 

      

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12 

      

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    See Item 4.

     

    8


    CUSIP No. 87184Q107       13G

     

    1 

      

    NAMES OF REPORTING PERSONS

     

    Mr. Amaury Wittouck

    2 

      

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☐

     

    3 

      

    SEC USE ONLY

     

    4 

      

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Belgium

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    3,568,842*

       6    

    SHARED VOTING POWER

     

    0

       7    

    SOLE DISPOSITIVE POWER

     

    3,568,842*

       8    

    SHARED DISPOSITIVE POWER

     

    0

    9 

      

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,842*

    10 

      

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11 

      

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12 

      

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    *

    See Item 4.

     

    9


    Item 1(a).

    Name of Issuer:

    Syros Pharmaceuticals, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    35 Cambridge Park Drive, Cambridge, Massachusetts 02140

     

    Item 2(a).

    Name of Person Filing:

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

     

    Item 2(c).

    Citizenship:

    (i) Invus Public Equities, L.P. (“Invus Public Equities”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Bermuda limited partnership

    (ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (iii) Artal International S.C.A. (“Artal International”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg limited partnership

    (iv) Artal International Management S.A. (“Artal International Management”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (v) Artal Group S.A. (“Artal Group”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (vi) Westend S.A. (“Westend”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (vii) Stichting Administratiekantoor Westend (the “Stichting”)

    Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands

    Citizenship: Netherlands foundation

    (viii) Mr. Amaury Wittouck

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Belgium

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.001 par value per share (the “Shares”)

     

    10


    Item 2(e).

    CUSIP Number:

    87184Q107

     

    Item 3.

    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    This Item 3 is not applicable.

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    As of December 31, 2023, Invus Public Equities directly held (i) 2,505,013 Shares and (ii) warrants to purchase up to an additional 1,063,829 Shares, with an exercise price of $10.34 per Share and expiration date of September 16, 2027 (the “Warrants”), subject to the Beneficial Ownership Limitation (described below).

    Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares held by Invus Public Equities. The Geneva branch of Artal International, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Artal International Management, as the managing partner of Artal International, controls Artal International and, accordingly, may be deemed to beneficially own the Shares that Artal International may be deemed to beneficially own. Artal Group, as the sole stockholder of Artal International Management, controls Artal International Management and, accordingly, may be deemed to beneficially own the Shares that Artal International Management may be deemed to beneficially own. Westend, as the parent company of Artal Group, controls Artal Group and, accordingly, may be deemed to beneficially own the Shares that Artal Group may be deemed to beneficially own. The Stichting, as the majority stockholder of Westend, controls Westend and, accordingly, may be deemed to beneficially own the Shares that Westend may be deemed to beneficially own. Mr. Wittouck, as the sole member of the board of the Stichting, controls the Stichting and, accordingly, may be deemed to beneficially own the Shares that the Stichting may be deemed to beneficially own.

    Invus Public Equities is prohibited from exercising the Warrants if, as a result of such exercise, Invus Public Equities, together with its affiliates and certain other persons for whom beneficial ownership would be aggregated, would beneficially own more than 9.99% of the total number of Shares then issued and outstanding immediately after giving effect to the exercise (the “Beneficial Ownership Limitation”), which percentage may be changed at a holder’s election upon 61 days’ notice to the Issuer. Reporting Persons disclaim beneficial ownership of any Shares the issuance of which would violate such Beneficial Ownership Limitation.

    (b) Percent of class:

    As of December 31, 2023, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person’s cover page. Calculations of the percentage of Shares beneficially owned are based on 25,660,038 Shares outstanding as of the closing of the Issuer’s offering on December 21, 2023 based on information reported in the Issuer’s Prospectus Supplement filed with the Securities and Exchange Commission on December 19, 2023, plus (ii) 64,909 Shares issuable upon exercise of certain of the Warrants, which due to the Beneficial Ownership Limitation is the maximum number of Shares that could be issued upon exercise of the Warrants as of December 31, 2023.

     

    11


    (c) Number of shares as to which Invus Public Equities, Invus PE Advisors, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Wittouck has:

     

      (i)

    Sole power to vote or to direct the vote:

    3,568,842*

     

      (ii)

    Shared power to vote or to direct the vote:

    0

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    3,568,842*

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    0

     

    *

    Subject to the Beneficial Ownership Limitation described herein.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    This Item 6 is not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    This Item 7 is not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    This Item 8 is not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    This Item 9 is not applicable.

     

    Item 10.

    Certification.

    Each of the Reporting Persons hereby makes the following certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    12


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 9, 2024

     

    INVUS PUBLIC EQUITIES, L.P.
    By:   INVUS PUBLIC EQUITIES ADVISORS, LLC,
    its general partner
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    INVUS PUBLIC EQUITIES ADVISORS, LLC
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    ARTAL INTERNATIONAL S.C.A.
    By:   ARTAL INTERNATIONAL MANAGEMENT S.A.,
    its managing partner
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL INTERNATIONAL MANAGEMENT S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL GROUP S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Authorized Person
    WESTEND S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director


    STICHTING ADMINISTRATIEKANTOOR WESTEND
    By:   /s/ Amaury Wittouck
    Name:   Amaury Wittouck
    Title:   Sole Member of the Board
    MR. AMAURY WITTOUCK
    By:   /s/ Amaury Wittouck
    Get the next $SYRS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SYRS

    DatePrice TargetRatingAnalyst
    9/23/2021$20.00 → $23.00Buy
    Roth Capital
    More analyst ratings

    $SYRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Haas Jason bought $161,240 worth of shares (100,000 units at $1.61), increasing direct ownership by 407% to 124,552 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      9/12/24 5:00:03 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Chee Conley bought $160,680 worth of shares (100,000 units at $1.61), increasing direct ownership by 444% to 122,504 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      9/12/24 5:00:03 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akkaraju Srinivas bought $3,999,998 worth of shares (904,977 units at $4.42) (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      12/26/23 5:24:30 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

      KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: Boston, MA, (Headquarters: Boston, MA; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on February 26, 2025. Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant po

      4/15/25 1:20:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

      Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market ("Nasdaq") and the deregistration of its common stock in order to terminate and suspend the Company's reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). The Company today notified Nasdaq of its intention to voluntarily delist its shares of common stock from the Nasdaq Global Select Market. The Company intends to file a Form 25 with the Securities and Exchange Commission ("SEC") to effect the delisting

      2/28/25 4:05:00 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

      -- SELECT-MDS-1 Did Not Meet its Primary Endpoint -- -- Company to Discontinue Study, Review Full Data Set, and Evaluate Next Steps -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression did not meet its primary endpoint of complete response (CR) rate. Tamibarotene is Syros' proprietary oral, selective, retinoic acid receptor alpha (RARα) agonist. In the first 190

      11/12/24 4:30:00 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Syros Pharmaceuticals Inc.

      15-12G - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/20/25 5:01:35 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Syros Pharmaceuticals Inc.

      144 - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      3/14/25 4:43:00 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Syros Pharmaceuticals Inc.

      EFFECT - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/12/25 12:15:11 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Simonian Nancy A sold $10,016 worth of shares (37,070 units at $0.27), decreasing direct ownership by 90% to 4,000 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      12/4/24 5:00:05 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Simonian Nancy A sold $35,739 worth of shares (134,713 units at $0.27), decreasing direct ownership by 77% to 41,070 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/27/24 5:00:04 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Stephens Kristin sold $7,949 worth of shares (36,133 units at $0.22), closing all direct ownership in the company (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/20/24 5:00:16 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Syros Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of Syros Pharmaceuticals with a rating of Buy and set a new price target of $23.00 from $20.00 previously

      9/23/21 9:11:45 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners reiterated coverage on Syros Pharmaceuticals with a new price target

      Alliance Global Partners reiterated coverage of Syros Pharmaceuticals with a rating of and set a new price target of $14.00 from $18.00 previously

      3/5/21 4:01:58 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company

      -- Conley Chee, CCO and CBO, to succeed Nancy Simonian, M.D. as CEO; Dr. Simonian to retire as CEO, effective December 1, 2023, and will remain on the Board of Directors -- -- Planned workforce reduction of approximately 35% sharpens focus of organization on late-stage development of tamibarotene in MDS and AML and ongoing pre-launch activities -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced a strategic realignment to prioritize key development and pre-launch activities to advance tamibarotene for the frontline treatment of higher-risk myelodysplastic

      10/2/23 8:45:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer

      Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer. Mr. Haas brings more than 25 years of healthcare investment banking and corporate finance experience to Syros. "We are pleased to welcome Jason to Syros, who brings an exceptional depth of financial, strategic, and leadership experience in the life sciences space," said Nancy Simonian, M.D., Chief Executive Officer of Syros. "Jason has a proven track record as a strategic advisor to biotechnology and pharmaceutical companies across all stages of development. He joins Syros at a pivotal time, as we advan

      10/12/21 8:00:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRS
    Financials

    Live finance-specific insights

    See more
    • Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

      KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: Boston, MA, (Headquarters: Boston, MA; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on February 26, 2025. Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant po

      4/15/25 1:20:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

      -- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected in Mid-November -- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2024 and provided a business update. "It is a very exciting time at Syros, as we approach a significant milestone in our efforts to establish tamibarotene as a potential new standard of care for higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. We expect to announ

      10/31/24 7:30:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

      Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 31, 2024 to report its third quarter 2024 financial results and provide a business update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (international) and refer to conference ID 07454. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 da

      10/24/24 7:08:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/14/24 5:28:08 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/14/24 5:24:48 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/14/24 5:05:24 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care